...began the final phase of disgorging its assets. It granted worldwide rights to EntoTAG-1 to Sinphar Pharmaceutical...
...Helmholtz Zentrum München GmbH, Neuherberg, Germany Immunocore Ltd., Abingdon, U.K. Medigene AG (Xetra:MDG1), Martinsried, Germany Sinphar Pharmaceutical Co. Ltd....

...The IPO price values the company at NT$5 billion ($165.1 million). SynCore, a subsidiary of Sinphar Pharmaceutical Co. Ltd....

...leaves (see BioCentury, March 23, 2011 & March 25, 2013). Medigene AG (Xetra:MDG1), Martinsried, Germany Sinphar Pharmaceutical Co. Ltd....

...first trade as an emerging stock for at least six months or meet other requirements. Sinphar Pharmaceutical Co. Ltd....

...product (see BioCentury, July 16, 2012 & June 10, 2013). Medigene AG (Xetra:MDG), Martinsried, Germany Sinphar Pharmaceutical Co. Ltd....

...ointment to treat external genital warts. Medigene expects the SynCore Biotechnology Co. Ltd. subsidiary of Sinphar Pharmaceutical Co. Ltd....

...the U.S. for the indication (see BioCentury, July 16, 2012). Medigene AG (Xetra:MDG), Martinsried, Germany Sinphar Pharmaceutical Co. Ltd....

...Co. Ltd. (Tokyo:8031, Tokyo, Japan) (see BioCentury, May 23, 2011). Medigene AG (Xetra:MDG), Martinsried, Germany Sinphar Pharmaceutical Co. Ltd....

...cancer, for which it has completed a Phase II trial. Medigene AG (Xetra:MDG), Martinsried, Germany Sinphar Pharmaceutical Co. Ltd....

...products. The compound has Fast Track designation in the U.S. MacuClear Inc. , Plano, Texas Sinphar Pharmaceutical Co. Ltd....